Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis

GAR-936, a novel glycylcycline, was investigated with a rat model of experimental endocarditis. It was compared with vancomycin against both vancomycin-susceptible and -resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus. GAR-936 exhibited the lowest MICs (≤0.12 μg/ml) in...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Murphy, Timothy M., Deitz, Jacqueline M., Petersen, Peter J., Mikels, Susan M., Weiss, William J.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2000
Assuntos:	Experimental Therapeutics
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101597/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036017/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3022-3027.2000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!